Enveric Biosciences announced the immediate exercise of outstanding warrants to purchase shares at reduced prices.
The exercise is expected to bring in approximately $3.1 million in gross proceeds.
H.C. Wainwright & Co. is the exclusive placement agent for the offering.
Exercise of Warrants
426,390 shares will be purchased at a reduced price of $7.05 per share, generating $3.1 million in gross proceeds.
New Unregistered Warrants
Company will issue new unregistered series E and F warrants to purchase common stock at $7.05 per share.
Offering Details
Expected to close on December 12, 2025, with proceeds allocated for product development and general corporate purposes.
- The exercise of warrants indicates investor confidence in Enveric Biosciences' future prospects.
- The additional funds will support the company's ongoing research and development efforts.
Enveric Biosciences' successful exercise of warrants demonstrates investor interest and provides crucial funding for its continued growth.